Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice

Jong Ho Kim, Yoo Shin Kim, Kyeongsoon Park, Seulki Lee, Hae Yun Nam, Kyung Hyun Min, Hyung Gon Jo, Jae Hyung Park, Kuiwon Choi, Seo Young Jeong, Rang Woon Park, In San Kim, Kwangmeyung Kim, Ick Chan Kwon

Research output: Contribution to journalArticlepeer-review

368 Scopus citations


To make a tumor targeting nano-sized drug delivery system, biocompatible and biodegradable glycol chitosan (Mw = 250 kDa) was modified with hydrophobic cholanic acid. The resulting hydrophobically modified glycol chitosans (HGCs) that formed nano-sized self-aggregates in an aqueous medium were investigated as an anticancer drug carrier in cancer treatment. Insoluble anticancer drug, cisplatin (CDDP), was easily encapsulated into the hydrophobic cores of HGC nanoparticles by a dialysis method, wherein the drug loading efficiency was about 80%. The CCDP-encapsulated HGC (CDDP-HGC) nanoparticles were well-dispersed in aqueous media and they formed a nanoparticles structure with a mean diameter about 300-500 nm. As a nano-sized drug carrier, the CDDP-HGC nanoparticles released the drug in a sustained manner for a week and they were also less cytotoxic than was free CDDP, probably because of sustained release of CDDP from the HGC nanoparticles. The tumor targeting ability of CDDP-HGC nanoparticles was confirmed by in vivo live animal imaging with near-infrared fluorescence Cy5.5-labeled CDDP-HGC nanoparticles. It was observed that CDDP-HGC nanoparticles were successfully accumulated by tumor tissues in tumor-bearing mice, because of the prolonged circulation and enhanced permeability and retention (EPR) effect of CDDP-HGC nanoparticles in tumor-bearing mice. As expected, the CDDP-HGC nanoparticles showed higher antitumor efficacy and lower toxicity compared to free CDDP, as shown by changes in tumor volumes, body weights, and survival rates, as well as by immunohistological TUNEL assay data. Collectively, the present results indicate that HGC nanoparticles are a promising carrier for the anticancer drug CDDP.

Original languageEnglish
Pages (from-to)41-49
Number of pages9
JournalJournal of Controlled Release
Issue number1
StatePublished - 7 Apr 2008

Bibliographical note

Funding Information:
This research was supported by the Intramural Research Program of KIST, by a grant (A062254) of the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea, and by a grant (07085KFDA180) from Korea Food & Drug Administration in 2007.


  • Cisplatin
  • Drug delivery system
  • Hydrophobically modified glycol chitosan
  • In vivo antitumor efficacy
  • Passive tumor targeting
  • Self-assembled nanoparticles


Dive into the research topics of 'Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice'. Together they form a unique fingerprint.

Cite this